


```
control
1
2
       mev 1 mM
       stat 20 \mu M
3
       stat 20 \mu\text{M} + mev 1 mM
       stat 5 \mu M + mev 1 mM
5
       statin 5 \mu M
6
       tam 0.5 \mu M
7
       tam 0.5 \mu M + estradiol 100 nm
8
       tamoxifen 0.5 \muM + mev 1 mM
9
       PBPE 5 \mu M
10
       PBPE 5 \mu M + estradiol 100 nM
11
       PBPE 5 \mu M + mev 1 mM
12
       anti-steroidal 1 \mu M
13
       anti-steroidal 10 \mu M
14
       anti-steroidal 50 \mu M
15
```

mev = mevalonate
stat - statin
tam = tamoxifen


FIGURE 4

#### Stable clone transient 138R17-4G-CVLs



Histogram of the activity (dose response) of a biphosphonate and of tamoxifen

```
control clone with transient 4G-CVLS
     + biphosphonate 0.1 \mu M
2
3
     + biphosphonate 0.5 \muM
     + biphosphonate 1 \mu M
4
     + biphosphonate 5 \muM
5
     + biphosphonate 10 \mu \mathrm{M}
6
     + biphosphonate 1 \mu \text{M} + mevalonate (mevalolactone) 50 \mu \text{M}
7
     + biphosphonate 1 \mu M + mevalonate (mevalolactone) 250 \mu M
8
     + biphosphonate 5 \mu M
9
     + biphosphonate 1 \mu M + farnesol 5 \mu M
10
     + biphosphonate 1 \mu M + farnesol 10 \mu M
11
     + tamoxifen 0.01 \mu M
12
     + tamoxifen 0.05 \mu M
13
     + tamoxifen 0.1 \mu M
14
     + tamoxifen 0.5 \mu M
15
     + tamoxifen 1 \mu M
16
```



A.	YFP	YFP-CVLS	YFP-CVLL	YFP-SVLS
DMSO				
FTI 277 (1 µ₩)	,			
B. aHA	R17-4G	R17-4G-CVLS	R17-4G-CVLL	R17-4G-SVLS
DMSO	-			
FTI 277 (1 μM)				
GGTI 298 (10 µM)			·	

